Market research
VAISHALI.NSE Vaishali Pharma Limited
NSE INR Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 1B
- P/E ratio
- 134.33
- Analyst target
- Not available
- Dividend yield
- Not available
- Beta
- 0.36
Profile
Company facts
- Exchange
- NSE
- Currency
- INR
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- ISIN
- INE972X01022
- Market cap
- 1B
- P/E ratio
- 134.33
- Analyst target
- Not available
- Dividend yield
- Not available
- Beta
- 0.36
About
About Vaishali Pharma Limited
Vaishali Pharma Limited engages in the pharmaceutical business in India and internationally. It offers a portfolio of active pharmaceutical ingredients, such as antibiotics, anti-ulcer, anti-inflammatory, analgesic, anti-pyretic, topical steroids, anti"malarial, cardiac, corticosteroids, anti-diabetics, anti-cold, anti-allergic, anti-diarrheal, anti-protozoal, anti-parasitic, excipients, anti-viral, anti-epileptic, anti-asthmatic, enzymes, anti-fungal, anti-platelet agent, skeletal muscle relaxant, and anti-helminitic. The company also provides formulations, including antibiotics, antibacterial, anti-platelet, laxative, anti-ulcer, enzymes, anti-asthmatic, anti-malarial, anti-cold, anti-allergic, anti-viral, anti-psychotic, anti-fungal, vitamins, topical steroids, corticosteroids, anti-inflammatory, analgesic, anti-pyretic, anti-diabetic, cardiac, and other products. In addition, it offers disposable surgical and casting tape products; herbal products; veterinary products; nutraceutical products; and oncology products. The company was formerly known as Vaishali Pharma Private Limited. Vaishali Pharma Limited was founded in 1989 and is based in Mumbai, India.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the VAISHALI.NSE discussion.
5 years, 4 months ago
Vaishali Pharma Limited is currently in a long term uptrend where the price is trading 6.5% above its 200 day moving average.
From a valuation standpoint, the stock is 83.3% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.8.
Vaishali Pharma Limited's total revenue sank by 3.4% to $100M since the same quarter in the previous year.
Its net income has increased by 33.2% to $8M since the same quarter in the previous year.
Finally, its free cash flow grew by 49.4% to $3M since the same quarter in the previous year.
Based on the above factors, Vaishali Pharma Limited gets an overall score of 4/5.